View clinical trials related to HTLV-1 Infection.
Filter by:This phase II trial studies how well nivolumab works in treating patients with human T-cell leukemia virus (HTLV)-associated T-cell leukemia/lymphoma. Nivolumab is an antibody, which is a type of blood protein that tags infected cells and other harmful agents. Nivolumab works against a protein called programmed cell death (PD)-1 and may help the body destroy cancer cells by helping the immune system to keep fighting cancer.
Background: - Information and samples collected from participants in medical research studies can be useful even after the original study is complete. Researchers can use the information and samples to learn more about multiple sclerosis or other immune system disorders. They can also be used for research into other disorders. Researchers would like to get permission to use samples collected from older studies to launch new lines of research. Objectives: - To look at information and samples from earlier National Institutes of Health Neuroimmunology Branch studies. Eligibility: - People who provided samples and medical information for earlier studies. Design: - Researchers will contact people who took part in earlier studies. Researchers will ask if they can study previously collected data and samples. - Data and samples may include physical exam data and psychological test results. Imaging study results are included. Preserved samples of body fluids and tissues may be studied. These include blood and urine samples. - No new treatment will be provided as part of this research study.